Women who developed meningioma after using Depo-Provera or Depo-SubQ injections may qualify for significant compensation. Free case review.
Confidential. No obligation. Takes about 2 minutes.
If most of the following apply to you, you may have a strong case. Our team will review your eligibility for free.
Estimated potential settlement value range for severe meningioma cases. Individual outcomes depend on tumor severity, surgery, lasting impairment, and other factors.
Estimates based on comparable pharmaceutical MDL settlements. Past results do not guarantee future outcomes.Established in 2000, we've connected tens of thousands of injury victims with leading mass tort attorneys nationwide.
Cases are handled on contingency by our network attorneys. You pay nothing up front and nothing unless your case is successful.
From the first defective drug litigation in our 30-year history to today's mass torts, we've helped countless victims connect with experienced attorneys.
Complete our 2-minute confidential intake form. Tell us about your Depo-Provera use and diagnosis.
Our case specialists review your information and assess your eligibility — at no cost to you.
If you qualify, we connect you with a network attorney experienced in Depo-Provera litigation.
The Judicial Panel on Multidistrict Litigation consolidated federal Depo-Provera meningioma cases into MDL 3140 (N.D. Fla.) under Judge M. Casey Rodgers in early 2025 to streamline pretrial proceedings.
A large French case-control study published in The BMJ in March 2024 found that prolonged use of injectable medroxyprogesterone acetate was associated with a 5.6× increased risk of intracranial meningioma.
Lawsuits allege Depo-Provera labels in the EU, UK, and Canada have warned about meningioma risk for years, while U.S. labels did not — and that Pfizer failed to warn American patients and physicians.
Peer-reviewed research, including a large 2024 study published in The BMJ, found that prolonged use of injectable medroxyprogesterone acetate (Depo-Provera) was associated with a meaningfully elevated risk of intracranial meningioma compared to non-users. Plaintiffs allege Pfizer failed to warn U.S. patients of this risk despite warnings on labels in other countries.
Meningioma is a tumor that arises from the meninges — the protective membranes surrounding the brain and spinal cord. Most meningiomas are non-cancerous (benign) but can still cause severe symptoms including headaches, vision changes, seizures, hearing loss, and require surgery, radiation, or both.
Possibly. Statute of limitations depends on your state and when you were diagnosed (not when you stopped using Depo). If your diagnosis was within the last 3 years, you likely still have time to file, but timelines are strict. Submit your information for a free eligibility check.
Eventually, yes — your case will require medical documentation of your meningioma diagnosis and your Depo-Provera use history. Our team can help retrieve these records on your behalf at no cost.
Settlement values depend on the severity of your tumor, surgery and treatment costs, lost wages, and ongoing impact on your life. Mass tort settlements for severe injuries have historically ranged from tens of thousands to several million dollars. No outcome is guaranteed.
Each state has its own statute of limitations, typically two to six years from the date of diagnosis. Because the Depo-Provera MDL is actively progressing, waiting to file may put your claim at risk. We recommend submitting your information promptly.
Plaintiffs allege Pfizer (which acquired Depo-Provera through Pharmacia & Upjohn) knew or should have known about the increased meningioma risk associated with prolonged use, and failed to adequately warn American patients and physicians, even though product labels in other countries (including the EU and Canada) carried this warning.